Pleural Effusion Secondary to Multiple Myeloma. Is Daratumumab an Effective Treatment? A Case Report

Extramedullary Plasmacytoma (EM) disease is an aggressive presentation at diagnosis and relapse for multiple myeloma (MM) patients. EM plasmacytoma is divided into two groups: the first group comprises tumors that are extending directly from osteolytic bone lesions while the second results from plasmacytoma infiltration into soft tissues, with no relationship to the bone. Despite new therapies and monoclonal antibodies the survival for patients with EM plasmocytoma is poor. The involvement pleural is uncommon in Multiple Myeloma.

Download Full-text

Pulsatile Midline Solitary Plasmacytoma in the Frontal Head Region-A Case Report”

Bangladesh Journal of Neuroscience ◽

10.3329/bjn.v32i1.57412 ◽

2016 ◽

Vol 32 (1) ◽

pp. 39-42

Author(s):

Md Atikur Rahman ◽

Aklaque Hossain Khan ◽

Kanak Kanti Barua

Keyword(s):

Multiple Myeloma ◽

Differential Diagnosis ◽

Case Report ◽

Histological Examination ◽

Plasma Cells ◽

Extramedullary Plasmacytoma ◽

Solitary Plasmacytoma ◽

Rare Entity ◽

Head Region ◽

Malignant Plasma Cell

Primary craniocerebral plasmacytomas are uncommon and represent only 0.7 % of all plasmacytomas. In this case solitary plasmacytoma in the midline frontal head region of the skull and discuss the clinical features and prognosis of this tumor. Plasmacytoma can present as multiple myeloma, solitary plasmacytoma of the bone or extramedullary plasmacytoma. Solitary plasmacytoma is a rare entity that composes of malignant plasma cells and involves the bone to form only one or two lesions without evidence of disease dissemination. It accounts for only 4% of malignant plasma cell tumors. 50 years old male was suffering from plasmacytoma in the frontal head region in our case which is pulsatile. On images showed multiple differential diagnosis but after operation histological examination revealed plasmacytoma. Bangladesh Journal of Neuroscience 2016; Vol. 32 (1): 39-42

Download Full-text

Relapse of multiple myeloma presenting as extramedullary plasmacytoma surrounding the aorta: a rare case report

Hematology Transfusion and Cell Therapy ◽

10.1016/j.htct.2020.09.094 ◽

2020 ◽

Vol 42 ◽

pp. 52

Author(s):

O. Ekinci ◽

A. Dogan ◽

M. Aslan ◽

S. Ebinc ◽

C. Demir

Keyword(s):

Multiple Myeloma ◽

Case Report ◽

Rare Case ◽

Extramedullary Plasmacytoma ◽

Rare Case Report

Download Full-text

Monoclonal Antibodies for the Treatment of Multiple Myeloma—A New Paradigm

Oncology & Hematology Review (US) ◽

10.17925/ohr.2015.11.02.115 ◽

2015 ◽

Vol 11 (02) ◽

pp. 115

Author(s):

Nidhi Tandon ◽

Shaji K Kumar ◽

◽

Keyword(s):

Multiple Myeloma ◽

Monoclonal Antibodies ◽

Vascular Endothelial ◽

New Paradigm ◽

Hematopoietic Stem ◽

New Therapies ◽

Significant Survival ◽

Frontline Treatment ◽

Cluster Of Differentiation ◽

Endothelial Growth Factor

The past decade has seen many promising new therapies emerge for the treatment of multiple myeloma (MM), resulting in improved survival of patients. Despite these improvements, the disease eventually becomes refractory to the available options and patients die of progressive disease. Development of new therapies with new modes of action remains critical for the continued improvement in outcome, and given the success of monoclonal antibodies (MoAbs) in other cancers there has been considerable interest in development of this class of drugs for MM. Past attempts with MoAbs against interleukin-6 (IL-6) as well as vascular endothelial growth factor (VEGF) targeted antibodies have not realized the potential. More recently, development of MoAbs against SLAMF7 and cluster of differentiation 38 (CD38) have demonstrated considerable activity in MM, the former in combination and the latter as a single agents. At present, it remains to be defined how MoAb therapy can be most effectively incorporated into the current therapeutic paradigms that will help to achieve longer disease control and significant survival gains in patients with MM, either as short-term induction therapy, frontline treatment in transplant ineligible patients, or long-term maintenance therapy post autologous hematopoietic stem cell transplantation (ASCT)/induction cytotoxic therapy. Ongoing studies are examining the potential of several other targets on the plasma cell, using both naked antibodies as well as toxin conjugated MoAbs.

Download Full-text

Unilateral Multiple Extramedullary Plasmacytoma of the Choroid and Conjunctiva: A Case Report

Journal of VitreoRetinal Diseases ◽

10.1177/2474126419893175 ◽

2019 ◽

Vol 4 (2) ◽

pp. 152-156

Author(s):

Shymaa Mohamed ◽

Truman Silvasi ◽

Anthony Kubat ◽

Thomas Aaberg

Keyword(s):

Multiple Myeloma ◽

Case Report ◽

Radiation Dose ◽

Poor Prognosis ◽

Clinical Manifestations ◽

Excisional Biopsy ◽

Extramedullary Plasmacytoma ◽

Eye Pain ◽

History Of ◽

Conjunctival Nodule

Purpose: We report a case of multiple extramedullary plasmacytoma (EMP) of the choroid and conjunctiva as a sign of multiple myeloma (MM) relapse. Methods: An observational case report with clinicopathologic correlation is presented. Results: A 45-year-old man with a 2.5-year history of MM presented with left eye pain. Examination revealed a conjunctival nodule and choroidal infiltrate in the left eye. Excisional biopsy demonstrated plasmacytoma of the conjunctiva and choroid. Despite radiotherapy and chemotherapy, multiple EMP recurred and the patient died 8 months after initial presentation. Conclusions: Multiple EMP of the choroid and conjunctiva has a poor prognosis and can present as a sign of MM relapse. Our imaging demonstrates the clinical manifestations of this tumor and can aid future diagnoses. Our radiation dose (20 Gy) was inadequate, which is an important reportable factor for future patients.

Download Full-text